Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.58 |
| ▸ | CCR1 | P32246 | 2/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | POLA1 | P09884 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756974 | 0.91 | ELANE (0.62) | ELANECCR1PTGER1CNR1CNR2 | |
| SCHEMBL5756619 | 0.89 | ELANE (0.60) | ELANECCR1PTGER1CNR1CNR2 | |
| SCHEMBL5759883 | 0.88 | ELANE (0.58) | ELANECCR1PTGER1CNR1CNR2 | |
| SCHEMBL5756437 | 0.87 | ELANE (0.56) | ELANECCR1PTGER1CNR1CNR2 | |
| SCHEMBL5757982 | 0.87 | ELANE (0.57) | ELANEPTGER1TP53HPGDMAPT | |
| SCHEMBL5758113 | 0.86 | ELANE (0.57) | ELANECCR1PTGER1 | |
| SCHEMBL5756834 | 0.86 | ELANE (0.78) | ELANECCR1CNR1CNR2HPGD | |
| SCHEMBL5756279 | 0.85 | CNR1 (0.54) | ELANECCR1PTGER1CNR1CNR2 | |
| SCHEMBL5761223 | 0.85 | ELANE (0.55) | ELANECCR1PTGER1CNR1CNR2 | |
| SCHEMBL5758863 | 0.84 | ELANE (0.56) | ELANEPTGER1TP53HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885CCR1 186/4885PTGER1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.